Screener
Protagonist Therapeutics PTGX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other payables | 21,667 | 28,269 |
| Deferred revenue | 9,659 | 9,550 |
| Operating lease liability | 2,396 | 2,283 |
| Total current liabilities | 37,181 | 45,441 |
| Operating lease liability - noncurrent | 6,820 | 8,040 |
| Total liabilities | 44,001 | 53,481 |
| Commitments and contingencies | ||
| Stockholders’ equity: |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's total current liabilities?
- Protagonist Therapeutics (PTGX) reported total current liabilities of $37.18M in Q2 2026.
- How has Protagonist Therapeutics's total current liabilities changed year-over-year?
- Protagonist Therapeutics's total current liabilities increased by 4.7% year-over-year, from $35.51M to $37.18M.
- What is the long-term trend for Protagonist Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's total current liabilities has grown at a 2.5% compound annual growth rate (CAGR), from $40.24M to $45.44M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Protagonist Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude